Network Pharmacology and Experimental Verification Reveal the Regulatory Mechanism of Chuanbeimu in Treating Chronic Obstructive Pulmonary Disease
Meilan Xian,Jiaoyuan Xu,Yamei Zheng,Lei Zhang,Jie Zhao,Jie Chen,Siguang Li,Lingsang Lin,Yi Zhong,Zehua Yang,Tian Xie,Linhui Huang,Yipeng Ding
DOI: https://doi.org/10.2147/copd.s442191
2024-03-21
International Journal of COPD
Abstract:Meilan Xian, 1, 2, &ast Jiaoyuan Xu, 1, 3, &ast Yamei Zheng, 4 Lei Zhang, 4 Jie Zhao, 4 Jie Chen, 1 Siguang Li, 1 Lingsang Lin, 1 Yi Zhong, 4 Zehua Yang, 4 Tian Xie, 4 Linhui Huang, 4 Yipeng Ding 1, 4 1 Department of General Practice, Hainan Affiliated Hospital of Hainan Medical University, Hainan General Hospital, Haikou, Hainan, 570311, People's Republic of China; 2 Department of General Diseases, Hainan Chengmei Hospital, Haikou, Hainan, 570300, People's Republic of China; 3 Department of General Clinic, Longbo Health Hospital, Lingao County, Hainan, 571800, People's Republic of China; 4 Department of Pulmonary and Critical Care Medicine, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570311, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yipeng Ding; Linhui Huang, Department of General Practice, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan General Hospital, No. 19, Xiuhua Road, Xiuying District, Haikou, Hainan, 570311, People's Republic of China, Email ; Background: Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder in pulmonology. Chuanbeimu (CBM) is a traditional Chinese medicinal herb for treating COPD and has been widely utilized in clinical practice. However, the mechanism of CBM in the treatment of COPD remains incompletely understood. This study aims to investigate the underlying therapeutic mechanism of CBM for COPD using network pharmacology and experimental approaches. Methods: Active ingredients and their targets were obtained from the Traditional Chinese Medicine Systems Pharmacology database. COPD-associated targets were retrieved from the GeneCards database. The common targets for CBM and COPD were identified through Venn diagram analysis. Protein-protein interaction (PPI) networks and disease-herb-ingredient-target networks were constructed. Subsequently, the results of the network pharmacology were validated by molecular docking and in vitro experiments. Results: Seven active ingredients and 32 potential targets for CBM were identified as closely associated with COPD. The results of the disease-herb-ingredient-target network and PPI network showed that peimisine emerged as the core ingredient, and SRC, ADRB2, MMP2 , and NOS3 were the potential targets for CBM in treating COPD. Molecular docking analysis confirmed that peimisine exhibited high binding affinity with SRC, ADRB2, MMP2 , and NOS3 . In vitro experiments demonstrated that peimisine significantly upregulated the expression of ADRB2 and NOS3 and downregulated the expression of SRC and MMP2 . Conclusion: These findings indicate that CBM may modulate the expression of SRC, ADRB2, MMP2 , and NOS3 , thereby exerting a protective effect against COPD. Keywords: chuanbeimu, molecular docking, network pharmacology, experiment verification, chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition within pulmonary disease. In clinical practice, it is essential to consider respiratory difficulties, long-term chronic cough or expectoration, and recurrent lower respiratory tract infections when accompanied by long-term exposure to risk factors such as smoking, exposure to fumes, as well as air pollution. According to the 2022 revision of Global Initiative for Chronic Obstructive Lung Disease (GOLD), the initial assessment and diagnosis categorizes COPD into two categories: stable COPD and Acute exacerbation of COPD (AECOPD), based on evaluation results and characteristics. 1 The prevalence and mortality of COPD in China are increasing annually due to an aging population, an increasing number of smokers, and rising levels environmental pollution. According to World Health Organization (WHO) statistics, it is estimated that approximately 5.4 million individuals will succumb to COPD and associated diseases by 2060. 2 The pathogenesis of COPD remains elusive, however, studies reveal that lung parenchymal damage, inflammatory responses, and structural alterations are the most characteristic pathological changes in the occurrence and development of COPD. 3 Pulmonary function tests are currently objective indicator for the diagnosis and evaluation of COPD. When combined with the COPD Assessment Test (CAT), it can markedly improve the sensitivity of COPD diagnosis. 4 Currently, -Abstract Truncated-
respiratory system